PapersPMID:23307959
Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- crossover · 3 months
- Dose studied, every finding
- PEA 300 mg twice a day for three months
- Population, every finding
- Never-treated ocular hypertensive patients; randomized, double-blind, placebo-controlled crossover with two-month washout
What moved
How to read these marks →“Three-month PEA intake reduced IOP and led to significantly improved FMD values in OH patients compared to placebo, by ameliorating peripheral endothelial function, and its positive effect lasted longer than the period of PEA consumption.”
- Decreases intraocular pressure
very limited
- Increases flow-mediated dilation
very limited
Study record
- Design
- crossover trial
- Species
- human
- Population
- Never-treated ocular hypertensive (OH) patients, with healthy age-matched controls at baseline
- Participants
- 80
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 8